Analyzing...
Loading company...
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹31,724 Cr revenue.
COGS 41.1%, employees 14.1%.
“We are confident of achieving our internal margin target of 20 to 21% for FY26 as communicated earlier”
“Consolidated revenues grew by 6% year on year to 8,286 crores. EBITDA 1,678 crore with margin of 20.3%, demonstrating 7% year on year growth”
“European business delivered 18% year on year revenue growth to 2,480 crores (243M euros). Firmly on track to surpass 1 billion annual revenue milestone by end of FY26”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 10.0%▼ | 10.5% |
| ROCE | 15.1%▲ | 13.8% |
| Net Margin | 10.3%▲ | 8.7% |
| EBITDA Margin | 21.7%▲ | 16.0% |
| Debt To Equity | 0.21x | 0.21x |
| Rev Growth 3yr | 10.8%▲ | 5.8% |
| EPS Growth 3yr | 9.9%▲ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹33,182 Cr +4.6% | ₹31,724 Cr +9.4% | ₹29,002 Cr +16.7% | ₹24,855 Cr +6.0% | ₹23,455 Cr -5.3% | ₹24,775 Cr +7.3% | ₹23,099 Cr +18.1% | ₹19,564 Cr |
| Other Income | ₹548 Cr -11.8% | ₹622 Cr +11.6% | ₹557 Cr +91.8% | ₹291 Cr -9.3% | ₹320 Cr -15.9% | ₹381 Cr +341.8% | ₹86 Cr -25.5% | ₹116 Cr |
| Total Income | ₹33,730 Cr +4.3% | ₹32,346 Cr +9.4% | ₹29,559 Cr +17.6% | ₹25,146 Cr +5.8% | ₹23,776 Cr -5.5% | ₹25,155 Cr +8.5% | ₹23,185 Cr +17.8% | ₹19,679 Cr |
| COGS | ₹13,487 Cr +3.5% | ₹13,026 Cr +3.4% | ₹12,603 Cr +11.6% | ₹11,293 Cr +11.4% | ₹10,140 Cr +2.4% | ₹9,902 Cr +1.7% | ₹9,735 Cr +11.7% | ₹8,713 Cr |
| ₹28,480 Cr +4.5% | ₹27,248 Cr +9.1% | ₹24,970 Cr +10.9% | ₹22,522 Cr +11.3% | ₹20,244 Cr -1.6% | ₹20,571 Cr +6.0% | ₹19,400 Cr +17.6% | ₹16,503 Cr | |
| Profit Before Tax | ₹5,185 Cr +1.7% | ₹5,098 Cr +15.9% | ₹4,397 Cr +67.6% | ₹2,624 Cr -22.9% | ₹3,404 Cr -54.0% | ₹7,399 Cr +96.9% | ₹3,758 Cr +21.7% | ₹3,089 Cr |
| Exceptional Items | (₹65 Cr) | ₹0.00 Cr +100.0% | (₹192 Cr) | ₹0.00 Cr +100.0% | (₹128 Cr) ↓ Decline | ₹2,815 Cr ↑ Recovery | (₹26 Cr) +70.3% | (₹88 Cr) |
| ₹1,671 Cr +5.6% | ₹1,583 Cr +30.7% | ₹1,211 Cr +76.8% | ₹685 Cr -5.6% | ₹726 Cr -63.9% | ₹2,010 Cr +120.0% | ₹914 Cr +25.7% | ₹727 Cr | |
| Net Profit | ₹3,485 Cr +0.0% | ₹3,484 Cr +9.9% | ₹3,169 Cr +64.4% | ₹1,928 Cr -27.2% | ₹2,647 Cr -50.4% | ₹5,334 Cr +88.5% | ₹2,830 Cr +19.7% | ₹2,365 Cr |
| Profit (Owners) | ₹3,487 Cr +0.0% | ₹3,486 Cr +9.9% | ₹3,173 Cr +64.6% | ₹1,928 Cr -27.2% | ₹2,648 Cr -50.4% | ₹5,335 Cr +88.4% | ₹2,831 Cr +19.7% | ₹2,365 Cr |
| Minority Interest | (₹2 Cr) +13.4% | (₹2 Cr) +42.3% | (₹4 Cr) ↓ Decline | ₹0.15 Cr ↑ Recovery | (₹1 Cr) -2.0% | (₹1 Cr) +30.1% | (₹1 Cr) -534.8% | (₹0.23 Cr) |
| Other Comprehensive Income | ₹1,314 Cr +332.9% | ₹304 Cr +206.2% | ₹99 Cr -86.5% | ₹736 Cr +181.1% | ₹262 Cr | ₹5 Cr -98.3% | ₹287 Cr ↑ Recovery | (₹4 Cr) |
| EPS | ₹60.04 | ₹60.02 | ₹54.15 | ₹32.90 | ₹45.20 | ₹91.05 | ₹48.32 | ₹40.36 |
| Diluted Shares | ₹58 Cr | ₹58 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr | ₹59 Cr |
| Profit Or Loss Of Associates | (₹28 Cr) +10.9% | (₹32 Cr) -84.7% | (₹17 Cr) -47.0% | (₹12 Cr) +62.7% | (₹31 Cr) +43.6% | (₹55 Cr) -264.9% | (₹15 Cr) ↓ Decline | ₹3 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited has informed the Exchange about Schedule of investor meeting.
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet
Aurobindo Pharma Limited has informed the Exchange about Schedule of meet at BofA 2026 India Conference in Mumbai
Aurobindo Pharma Limited has informed the Exchange about Copy of Newspaper Publication
Aurobindo Pharma Limited has informed the Exchange about Acquisition
Aurobindo Pharma Limited has informed the Exchange about General Updates
Aurobindo Pharma Limited has informed the Exchange about schedule of Earnings Call to be held on May 22, 2026 at 8:30 AM (IST) on Audited Financial Results of the Company for the fourth quarter and ye...
Aurobindo Pharma Limited has submitted Copy of Newspaper Publication with regard to post buyback public advertisement.
Aurobindo Pharma Limited has informed the Exchange about classification of Unit-VII of Aurobindo Pharma Limited, as Voluntary Action Indicated (VAI)
Aurobindo Pharma Limited has informed the Exchange that CuraTeQ Biologics Private Limited, a wholly owned subsidiary of the Company Secures Health Canada NOC for Bevqolva Bevacizumab Biosimilar
Aurobindo Pharma Limited has informed the Exchange about Buyback
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral Liquid,1.1 grams pe...